Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

37.5%

3 terminated/withdrawn out of 8 trials

Success Rate

62.5%

-24.0% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

160%

8 of 5 completed trials have results

Key Signals

8 with results

Enrollment Performance

Analytics

Phase 2

5(62.5%)

Phase 1

2(25.0%)

Phase 3

1(12.5%)

8Total

Phase 2(5)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT02343952Phase 2Completed

Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC

Role: lead

NCT03041181Phase 2Terminated

Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor

Role: lead

NCT02499952Phase 2Terminated

Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors

Role: lead

NCT00216203Phase 1Completed

Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer

Role: lead

NCT00417248Phase 1Terminated

Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer

Role: lead

NCT00319735Phase 2Completed

Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas

Role: lead

NCT00216125Phase 3Completed

Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer

Role: lead

NCT00367601Phase 2Completed

Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer

Role: lead

All 8 trials loaded